{"id":17244,"date":"2021-10-28T13:18:44","date_gmt":"2021-10-28T11:18:44","guid":{"rendered":"http:\/\/mabdesign.fr\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/"},"modified":"2021-10-28T13:18:44","modified_gmt":"2021-10-28T11:18:44","slug":"promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/","title":{"rendered":"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS"},"content":{"rendered":"

Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by mass spectrometry<\/strong><\/p>\n

October 22, Lyon – After 10 years of research and development, Promise Proteomics<\/strong> is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.
\n\u201cmAbXmise kits are a unique patented solution combining labelled monoclonal antibodies, reagents and laboratory supplies to quantify therapeutic monoclonal antibodies. This multiplexed method outperforms other analytical methods, thus providing scientific, clinical and economic perspectives that fully meet the constraints of routine therapeutic drug monitoring\u201d indicates Doroth\u00e9e LEBERT, CSO of Promise Proteomics. To know more<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

After 10 years of research and development, Promise Proteomics is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32,18],"tags":[],"class_list":["post-17244","post","type-post","status-publish","format-standard","hentry","category-news","category-our-members","category-uncategorized"],"yoast_head":"\nPromise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS - MabDesign<\/title>\n<meta name=\"description\" content=\"After 10 years of research and development, Promise Proteomics is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS - MabDesign\" \/>\n<meta property=\"og:description\" content=\"After 10 years of research and development, Promise Proteomics is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-28T11:18:44+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS\",\"datePublished\":\"2021-10-28T11:18:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/\"},\"wordCount\":128,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/\",\"name\":\"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2021-10-28T11:18:44+00:00\",\"description\":\"After 10 years of research and development, Promise Proteomics is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS - MabDesign","description":"After 10 years of research and development, Promise Proteomics is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/","og_locale":"en_US","og_type":"article","og_title":"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS - MabDesign","og_description":"After 10 years of research and development, Promise Proteomics is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.","og_url":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/","og_site_name":"MabDesign","article_published_time":"2021-10-28T11:18:44+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS","datePublished":"2021-10-28T11:18:44+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/"},"wordCount":128,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/","url":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/","name":"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2021-10-28T11:18:44+00:00","description":"After 10 years of research and development, Promise Proteomics is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/promise-proteomics-announces-ce-ivd-marking-of-its-mabxmise-kits-for-therapeutic-drug-monitoring-by-ms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by MS"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=17244"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17244\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=17244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=17244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=17244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}